ArticleFrontiers in immunology2026
Case Report: Presenting as optic neuritis-a biopsy-proven IgG4 anti-NF155-positive combined central and peripheral demyelination syndrome.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined central and peripheral demyelination (CCPD) is a condition characterized by concurrent demyelination in both the central and peripheral nervous systems. To date, cases of CCPD presenting with isolated optic neuritis as the initial manifestation and positive for anti-neurofascin 155 (anti-NF155) antibodies are exceedingly rare. We herein report a case of a young male positive for anti-NF155 antibodies who developed severe optic neuritis and was subsequently diagnosed with CCPD via histopathological examination. This case highlights that CCPD may develop in patients presenting with optic neuritis as the initial manifestation, and underscores the critical importance of anti-NF155 antibody testing when concomitant peripheral neuropathy is identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.